Home » Stocks » GTHX

G1 Therapeutics, Inc. (GTHX)

Stock Price: $10.99 USD -0.20 (-1.79%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $11.50 +0.51 (4.64%) Oct 30, 7:07 PM

Stock Price Chart

Key Info

Market Cap 417.78M
Revenue (ttm) 2.14M
Net Income (ttm) -130.04M
Shares Out 38.01M
EPS (ttm) -3.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $10.99
Previous Close $11.19
Change ($) -0.20
Change (%) -1.79%
Day's Open 11.14
Day's Range 10.81 - 11.36
Day's Volume 655,253
52-Week Range 8.80 - 31.38

More Stats

Market Cap 417.78M
Enterprise Value 210.84M
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 38.01M
Float 27.97M
EPS (basic) -3.46
EPS (diluted) -3.45
FCF / Share -3.00
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.85M
Short Ratio 8.55
Short % of Float 24.50%
Beta 2.05
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 195.22
PB Ratio 2.36
Revenue 2.14M
Operating Income -135.36M
Net Income -130.04M
Free Cash Flow -113.33M
Net Cash 206.94M
Net Cash / Share 5.44
Gross Margin n/a
Operating Margin -6,325.19%
Profit Margin n/a
FCF Margin -5,295.98%
ROA -28.45%
ROE -50.35%
ROIC -1,338.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy 8
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(417.38% upside)
Current: $10.99
Target: 56.86
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit----0.52
Operating Income-129-89.29-60.97-30.39-15.42
Net Income-122-85.29-60.12-30.29-20.26
Shares Outstanding37.5033.3218.201.491.34
Earnings Per Share-3.27-2.56-3.57-23.33-16.13
Operating Cash Flow-99.57-74.31-50.52-25.14-13.85
Capital Expenditures-2.72-0.71-0.29-0.25-0.09
Free Cash Flow-102-75.02-50.81-25.39-13.93
Cash & Equivalents27036910447.3122.94
Total Debt9.54----
Net Cash / Debt26036910447.3122.94
Book Value25635993.39-64.99-31.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name G1 Therapeutics, Inc.
Country United States
Employees 104
CEO Mark A. Velleca

Stock Information

Ticker Symbol GTHX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GTHX
IPO Date May 17, 2017


G1 Therapeutics, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.